EXTRACELLULAR VESICLES DERIVED FROM GRAM-POSITIVE BACTERIA, AND USE THEREOF

• US 20120159658A1
• Filed: 08/26/2010
• Published: 06/21/2012
• Est. Priority Date: 09/01/2009
• Status: Active Grant

• Current Assignee: Aeon Medix Inc.
• Original Assignee: Aeon Medix Inc.
• Inventors: Gho, Yong Song, Kim, Yoon Keun, Lee, Eun Young, Hong, Sung Wook, Kim, Ji Hyun, Choi, Seng Jin
• Granted Patent: US 8,969,653 B2
• Time in Patent Office: Days
• US Class Current: 800/9
• CPC Class Codes: A01K 2207/00 Modified animals
• CPC Class Codes: A01K 2267/0375 Animal model for cardiovascular diseases
• CPC Class Codes: A61P 31/04 Antibacterial agents
• CPC Class Codes: A61P 37/04 Immunostimulants
• CPC Class Codes: A61P 9/10 for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• CPC Class Codes: C12P 1/04 by using bacteria
• CPC Class Codes: C12Q 1/6883 for diseases caused by alterations of genetic material
• CPC Class Codes: C12Q 2600/158 Expression markers
• CPC Class Codes: Y02P 20/582 Recycling of unreacted starting or intermediate materials

Abstract

The present application relates to extracellular vesicles (EVs) derived from gram-positive bacteria. In detail, the present application provides animal models of disease using extracellular vesicles derived from gram-positive bacteria, provides a method for screening an active candidate substance which is capable of preventing or treating diseases through the animal models of disease, provides vaccines for preventing or treating diseases caused by extracellular vesicles derived from gram-positive bacteria, and provides a method for diagnosing the causative factors of diseases caused by gram-positive bacteria using extracellular vesicles.

Claims

1. Extracellular vesicles derived from Gram-positive bacteria.

7. The extracellular vesicles of claim 1, being isolated from an internal body secretion from an animal.

9. The extracellular vesicles of claim 1, being isolated from a surrounding environment.

11. The extracellular vesicles of claim 1, being isolated from a culture of Gram-positive bacteria.

2. (canceled)

3. (canceled)

4. (canceled)

5. (canceled)

6. (canceled)

8. (canceled)

10. (canceled)

12. (canceled)

13. (canceled)

14. (canceled)

15. (canceled)

16. (canceled)

17. A disease animal model, established using Gram-positive bacteria-derived extracellular vesicles.

29. The disease animal model of claim 17, wherein the disease is selected from the group consisting of a dermal disease, a respiratory disease, a digestive disease, a genital disease, a vascular disease, a metabolic disease, a lung disease, a bone disease, and a cranial nerve disease.

18. (canceled)

19. (canceled)

20. (canceled)

21. (canceled)

22. (canceled)

23. (canceled)

24. (canceled)

25. (canceled)

26. (canceled)

27. (canceled)

28. (canceled)

30. (canceled)

31. (canceled)

32. (canceled)

33. (canceled)

34. (canceled)

35. (canceled)

36. (canceled)

37. (canceled)

38. (canceled)

39. (canceled)

40. A method for establishing a disease animal model, comprising administering Gram-positive bacteria-derived extracellular vesicles to an animal.

41. (canceled)

42. A method for discovering a biomarker, using a disease animal model established with Gram-positive bacteria-derived extracellular vesicles.

43. A method for screening a drug candidate preventive or therapeutic of a disease caused by Gram-positive bacteria-derived extracellular vesicles.

64. The method of claim 43, comprising applying Gram-positive bacteria-derived extracellular vesicles to cells.

44. (canceled)

45. (canceled)

46. (canceled)

47. (canceled)

48. (canceled)

49. (canceled)

50. (canceled)

51. (canceled)

52. (canceled)

53. (canceled)

54. (canceled)

55. (canceled)

56. (canceled)

57. (canceled)

58. (canceled)

59. (canceled)

60. (canceled)

61. (canceled)

62. (canceled)

63. (canceled)

65. (canceled)

66. (canceled)

67. (canceled)

68. A vaccine for preventing or treating a Gram-positive bacteria infection, comprising Gram-positive bacteria-derived extracellular vesicles.

75. The vaccine of claim 68, wherein the vaccine is modified using transformed bacteria or by treating the bacteria with a compound.

78. The vaccine of claim 68, wherein the vaccine is modified by treating the extracellular vesicles with a compound.

79. The vaccine of claim 68, wherein the vaccine is used in combination with a drug to enhance medicinal efficacy or alleviate side effects.

69. (canceled)

70. (canceled)

71. (canceled)

72. (canceled)

73. (canceled)

74. (canceled)

76. (canceled)

77. (canceled)

80. (canceled)

81. (canceled)

82. (canceled)

83. (canceled)

84. (canceled)

85. (canceled)

86. (canceled)

87. (canceled)

88. (canceled)

89. (canceled)

90. (canceled)

91. (canceled)

92. (canceled)

93. (canceled)

94. (canceled)

95. (canceled)

96. (canceled)

97. (canceled)

98. (canceled)

99. (canceled)

100. (canceled)

101. (canceled)

102. (canceled)

103. (canceled)

104. A method for preventing or treating a disease, comprising administering Gram-positive bacteria-derived extracellular vesicles at a sublethal dose to a mammal.

105. (canceled)

106. (canceled)

107. (canceled)

108. (canceled)

109. (canceled)

110. (canceled)

111. (canceled)

112. (canceled)

113. (canceled)

114. (canceled)

115. (canceled)

116. (canceled)

117. (canceled)

118. (canceled)

119. (canceled)

120. (canceled)

121. A method for diagnosing a pathogenic factor, using Gram-positive bacteria-derived extracellular vesicles.

128. The method of claim 121, comprising analyzing a base sequence of a genetic substance present within the Gram-positive bacteria-derived extracellular vesicles.

130. The method of claim 121, comprising analyzing a protein present in the Gram-positive bacteria-derived extracellular vesicles.

131. The method of claim 121, comprising analyzing an immune response to the Gram-positive bacteria-derived extracellular vesicles.

133. The method of claim 121, wherein the pathogenic factor is obtained from a secretion selected from the group consisting of skin lavage fluid, snivel, phlegm, feces, blood, urine, synovial, cerebrospinal fluid, pleural fluid, and ascites.

122. (canceled)

123. (canceled)

124. (canceled)

125. (canceled)

126. (canceled)

127. (canceled)

129. (canceled)

132. (canceled)